Jaguar Health Dirección

Dirección controles de criterios 3/4

El CEO de Jaguar Health's es Lisa Conte , nombrado en Jun 2013, tiene una permanencia de 11.08 años. compensación anual total es $815.85K, compuesta por 70.6% salario y 29.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.002% de las acciones de la empresa, por valor de €407.84. La antigüedad media del equipo directivo y de la junta directiva es de 3.6 años y 6.3 años, respectivamente.

Información clave

Lisa Conte

Chief Executive Officer (CEO)

US$815.9k

Compensación total

Porcentaje del salario del CEO	70.6%
Permanencia del CEO	11.2yrs
Participación del CEO	0.002%
Permanencia media de la dirección	3.7yrs
Promedio de permanencia en la Junta Directiva	6.4yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Lisa Conte en comparación con los beneficios de Jaguar Health?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-US$36m
Mar 31 2024	n/a	n/a	-US$38m
Dec 31 2023	US$816k	US$576k	-US$41m
Sep 30 2023	n/a	n/a	-US$40m
Jun 30 2023	n/a	n/a	-US$44m
Mar 31 2023	n/a	n/a	-US$42m
Dec 31 2022	US$1m	US$603k	-US$47m
Sep 30 2022	n/a	n/a	-US$54m
Jun 30 2022	n/a	n/a	-US$54m
Mar 31 2022	n/a	n/a	-US$59m
Dec 31 2021	US$3m	US$527k	-US$53m
Sep 30 2021	n/a	n/a	-US$50m
Jun 30 2021	n/a	n/a	-US$46m
Mar 31 2021	n/a	n/a	-US$42m
Dec 31 2020	US$1m	US$500k	-US$39m
Sep 30 2020	n/a	n/a	-US$35m
Jun 30 2020	n/a	n/a	-US$39m
Mar 31 2020	n/a	n/a	-US$45m
Dec 31 2019	US$1m	US$500k	-US$45m
Sep 30 2019	n/a	n/a	-US$48m
Jun 30 2019	n/a	n/a	-US$43m
Mar 31 2019	n/a	n/a	-US$34m
Dec 31 2018	US$1m	US$480k	-US$32m
Sep 30 2018	n/a	n/a	-US$41m
Jun 30 2018	n/a	n/a	-US$30m
Mar 31 2018	n/a	n/a	-US$24m
Dec 31 2017	US$643k	US$440k	-US$22m

Compensación vs. Mercado: La compensación total de Lisa($USD815.85K) está por encima de la media de empresas de tamaño similar en el mercado German ($USD408.13K).

Compensación vs. Ingresos: La compensación de Lisa ha sido consistente con los resultados de la empresa en el último año.

CEO

Lisa Conte (65 yo)

11.2yrs

Permanencia

US$815,854

Compensación

Ms. Lisa A. Conte serves as a Scientific Advisor at Triton Funds LLC. She is a Former Member of Scientific Advisory Board at Triton Funds LLC. She founded Jaguar Health, Inc. (formerly known as Jaguar Anim...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Lisa Conte	Founder	11.2yrs	US$815.85k	0.0021% $ 226.8
Pravin Chaturvedi	Chief Scientific Officer & Chair of Scientific Advisory Board	2.4yrs	US$627.13k	0.00063% $ 67.1
Jonathan Wolin	Chief of Staff	5.8yrs	US$562.79k	0.00059% $ 62.8
Steven King	Chief of Sustainable Supply	9.9yrs	US$491.54k	0.00051% $ 54.3
Carol Lizak	Chief Financial Officer	4.4yrs	sin datos	0.00030% $ 31.9
Peter Hodge	Senior Director of Investor Relations	no data	sin datos	sin datos
Karen Brunke	Executive VP of Corporate & Business Development	2.9yrs	sin datos	sin datos
David Sesin	Chief Manufacturing Officer	no data	sin datos	sin datos
Ian Wendt	Chief Commercial Officer	3.7yrs	US$557.90k	sin datos
Massimo Radaelli	President of Jaguar International	less than a year	sin datos	sin datos
Catherine Collis	Senior Vice President of Growth Strategy	less than a year	sin datos	sin datos
Darlene Horton	Chief Medical Officer	no data	sin datos	sin datos

3.7yrs

Permanencia media

62yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 1JA se considera experimentado (3.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Lisa Conte	Founder	11.2yrs	US$815.85k	0.0021% $ 226.8
Pravin Chaturvedi	Chief Scientific Officer & Chair of Scientific Advisory Board	7.3yrs	US$627.13k	0.00063% $ 67.1
James Bochnowski	Independent Chairman	10.5yrs	US$140.98k	0.00066% $ 70.3
John Micek	Independent Director	8.3yrs	US$101.68k	0.00038% $ 40.5
Anula Jayasuriya	Independent Director	2.1yrs	US$77.61k	0.00051% $ 54.3
Jonathan Siegel	Independent Director	6.4yrs	US$104.18k	0.00042% $ 44.7
Sandra Swain	Member of Scientific Advisory Board	1.6yrs	sin datos	sin datos
Kelly Shanahan	Scientific Advisory Board	1.4yrs	sin datos	sin datos
Stacey Tinianov	Member of Scientific Advisory Board	1.3yrs	sin datos	sin datos

6.4yrs

Permanencia media

66yo

Promedio de edad

Junta con experiencia: La junta directiva de 1JA se considera experimentada (6.3 años de antigüedad promedio).

Jaguar Health Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Jaguar Health, Inc., Annual General Meeting, Jun 21, 2024

Jaguar Health, Inc. Appoints Massimo Radaelli, PhD, as President of Jaguar International

Jaguar Health, Inc., Annual General Meeting, Jul 07, 2023

Jaguar Health, Inc. Appoints Stacey Tinianov to Scientific Advisory Board

Jaguar Health, Inc. and Napo Pharmaceuticals Appoints Sandra M. Swain to the Scientific Advisory Board

Jaguar Health, Inc. Appoints Anula Jayasuriya to Board of Directors and Forms Business Development Advisory Committee

Recent updates

Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care At American Society for Radiation Oncology Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024

Jaguar Health, Inc. Announces Issuance of New Hong Kong Patent Bolsters Ip Protection for Jaguar Health in the Treatment of Short Bowel Syndrome

Jaguar Health, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Napo Pharmaceuticals Announces Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders

Jaguar Health, Inc. Reports Phase 3 Ontarget Trial Results for Its Cancer Supportive Care Drug Crofelemer

Jaguar Health Announces 1-For-60 Reverse Stock Split in Order to Support Compliance with Nasdaq's Listing Standards

First quarter 2024 earnings released: US$0.058 loss per share (vs US$2.39 loss in 1Q 2023)

Jaguar Health, Inc., Annual General Meeting, Jun 21, 2024

Jaguar Health, Inc. to Report Q1, 2024 Results on May 14, 2024

Jaguar Health, Inc. Establishes New Investigational New Animal Drug File with the Center for Veterinary Medicine of the U.S. Food and Drug Administration

Jaguar Health Receives Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement

Jaguar Health, Inc. Appoints Massimo Radaelli, PhD, as President of Jaguar International

Full year 2023 earnings released: US$1.79 loss per share (vs US$36.18 loss in FY 2022)

Jaguar Health, Inc. to Report Q4, 2023 Results on Apr 01, 2024

Jaguar Health Receives Notification Letter from The Nasdaq Stock Market LLC

Jaguar Health, Inc. Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Napo Pharmaceuticals, Inc. Announces Majority of Subjects in Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Continue on to Stage II

FDA Approves Renewal of Canalevia-CA1, Jaguar Health’s Drug for Chemotherapy-Induced Diarrhea in Dogs

Jaguar Health, Inc. announced that it has received $0.06 million in funding

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: US$0.38 loss per share (vs US$8.83 loss in 3Q 2022)

Jaguar Health Receives Additional 180-Day Grace Period to Regain Compliance with Nasdaq's Bid Price Rule

Jaguar Health, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Jaguar Health, Inc. Announces Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)

New major risk - Financial position

Second quarter 2023 earnings released: US$0.69 loss per share (vs US$8.82 loss in 2Q 2022)

Jaguar Health Announces FDA Activation of Third-Party Investigational New Drug Application for Evaluation of Crofelemer for Treatment of Uncontrolled Diarrhea in Patient with Short Bowel Syndrome

Napo Pharmaceuticals Submits Investigational New Drug Application to FDA for MicroVillus Inclusion Disease

New major risk - Market cap size

Jaguar Health, Inc., Annual General Meeting, Jul 07, 2023

Jaguar Health, Inc. Appoints Stacey Tinianov to Scientific Advisory Board

First quarter 2023 earnings released: US$2.39 loss per share (vs US$30.17 loss in 1Q 2022)

Jaguar Health Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

Jaguar Health, Inc. to Report Q1, 2023 Results on May 15, 2023

Jaguar Health, Inc. announced that it has received $1.86 million in funding

Jaguar Health, Inc. announced that it expects to receive $1.86 million in funding

Full year 2022 earnings released

Jaguar Health Regains Compliance with Nasdaq’s Bid Price Requirement

Jaguar Health, Inc. Provides Updates Regarding its Focus on Rare and Orphan Disease Indications in the U.S. & Europe

Jaguar Health, Inc. and Napo Pharmaceuticals Appoints Sandra M. Swain to the Scientific Advisory Board

Jaguar Health Announces Publication in Breast Cancer Research and Treatment of Investigator-Initiated Phase 2 HALT-D Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (Cid) in Breast Cancer Patients

European Medicines Agency Grants Orphan Drug Designation for Crofelemer for Microvillus Inclusion Disease

Jaguar Health Receives Additional 180-Day Grace Period to Regain Compliance with Nasdaq's Bid Price Rule

Jaguar Health, Inc. announced delayed 10-Q filing

Jaguar Health, Inc. Appoints Anula Jayasuriya to Board of Directors and Forms Business Development Advisory Committee

Jaguar Health, Inc. Announces Appointment of Pravin Chaturvedi as Chief Scientific Officer and Chair of the Scientific Advisory Board

Jaguar Health Regains Compliance with Nasdaq Bid Price Requirement

Jaguar Health Explores Possibility of Conditional Marketing Authorization for Proposed Inflammatory Diarrhea Indication for Crofelemer, Initially in ‘Long-Hauler’ Covid-19 Recovery Patients in Europe

Jaguar Health Got Letter from Nasdaq Staying Stipulation for Company to Comply with Minimum Bid Price Requirement by Dec. 23

New 90-day high: €0.40

Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. Plan to Study, Develop and Commercialize Crofelemer, the Company’s Novel Proprietary Drug, for an Indication of Inflammatory Diarrhea, Initially in Europe

Revenue misses expectations

Third quarter 2020 earnings released: US$0.20 loss per share

Jaguar Health Receives Positive Nasdaq Listing Determination

New 90-day low: €0.24

Jaguar Health, Inc. Announces Appointment of Melissa Yeager, J.D. as Senior Vice President, Regulatory Affairs and Quality Assurance

New 90-day low: €0.26

New 90-day low - €0.34

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad